Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00756340 · ClinicalTrials.gov registry record · Phase 1
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00756340 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 16 participants.
The verdict
NCT00756340, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main goals of this Phase I study are to learn about the side effects that may occur when everolimus and bevacizumab are given to children and young adults and to find the highest doses of these drugs that can be given together without causing severe side effects. Bevacizumab will be given into the vein (IV) over 30-90 minutes every two weeks and everolimus tablets will be given daily by mouth. A cycle of therapy will be four weeks.
Interventions
- DRUG Bevacizumab
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-07 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00756340
The ClinicalTrials.gov registry entry for NCT00756340 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00756340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00756340 about?
NCT00756340 is a clinical study titled "A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors". The main goals of this Phase I study are to learn about the side effects that may occur when everolimus and bevacizumab are given to children and young adults and to find the highest doses of these drugs that can be given together without causing severe side effects. Bevacizumab will be given into t...
What is the current status of trial NCT00756340?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2008-07. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00756340?
The interventions under investigation include: Bevacizumab (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT00756340?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.